1. Introduction {#s0005}
===============

The skin is the outermost and largest organ of the human body, covering an area of 1.8 m^2^ and making up close to one-fifth of an average person's total body mass ([@b0070]). Being the first barrier to entry into the body, the skin protects against external threats in the environment, including pathogens, harmful UV rays, toxins, inflammatory agents and dehydration ([@b0840]). Due to the large coverage area of the human skin tissue, it offers a convenient, selective, and non-invasive route for drug delivery. Transdermal drug delivery (TDD) refers to the delivery of therapeutic agents across the skin layer. The delivery of drugs via skin overcomes many of the issues associated with oral drug delivery, including the gastric irritation, elimination of hepatic first-pass metabolism, and poor patient compliance. Additionally, it offers better release over time compared to oral drug delivery ([@b0290], [@b0595]). Moreover, transdermal delivery devices are accessible, replaceable, controllable, and could be self-administered in several cases ([@b0515]). Scopolamine, with a primary indication for managing motion sickness (Transderm-Scop®), nicotine for smoking cessation (Nicoderm®), and fentanyl for chronic pain (Lexicomp-Online, 2016) are examples of the first generation trans-delivery drug administration is the remedy for disease.

The greatest challenge in the delivery of active ingredients across the transdermal route is the stratum corneum (SC) that acts as the first protective layer of the skin and limit the drug absorption. This will significantly reduce the effectiveness of delivery of therapeutic agents and limit the types of drugs that can be delivered into the skin. Recently, there have been several studies on microneedles that penetrate the superficial skin barrier (SC) while avoiding contact with important nerves and capillaries in the epidermis to provide a more efficient and quick method for drug delivery compared to available transdermal drug delivery strategies. The novel approach combines between conventional injection and patch system. The drug is delivered transdermally while removing the pain and invasiveness associated with conventional methods in medicine ([@b0380]).

Microneedles (MNs) have been conceptualized and introduced several years ago but were only successfully fabricated and applied in the 1990 s ([@b0225], [@b0270], [@b0605]). The classification of microneedles has been done according to the function it performs: solid, coated, hollow, dissolving and hydrogel-forming microneedles ([@b0005], [@b0655]). The mechanical properties and biocompatibility of the material chosen for the manufacture of MNs are of major importance to the performance of the MNs. Low production cost and high mechanical strength are general considerations for the choice of fabricating materials. In this regard, polymers are the preferred materials for MNs fabrication as it does not elicit an immune response in the body, degrades in the body and can be tailored to perform with different strengths and functions ([@b0440]).

Microneedles play an important role in medical field applications for delivering various drugs ranging from small to macromolecules, especially protein drugs that use for the treatment of several diseases. Thus, biotechnology companies give more attention toward research and development of MNs loaded protein drugs ([@b0370], [@b0470], [@b0645]). However, effective use of biotherapeutics is hindered by the large size, hydrophilic nature, poor absorption, and unstable nature of the drug, which prevent efficient uptake through the skin ([@b0645]). The progress in MNs research and production technology will lead to the delivery of clinically important drugs in the future ([@b0370]).

2. Anatomy of the skin {#s0010}
======================

The skin is a multidimensional organ made of three important layers ([@b0440]) as presented in [Fig. 1](#f0005){ref-type="fig"} . The layer's function to protect the internal organs from a host of outside dangers including toxins, external mechanical pressure, and microbial attack from pathogenic species. The skin also functions as a trigger for immune reactions due to the specialized antigen-presenting cells.Fig. 1Structure of Skin and routs of penetration of a molecule across the stratum corneum.

The first skin layer, i.e. the epidermis layer, is approximately 150--200 mm thick and is composed of viable cells. It is made of five layers according to a degree of cell keratinization: stratum corneum (SC, horny layer), stratum lucidum (clear layer), stratum granulosum (granular layer), stratum spinosum (spinous or prickle layer) and stratum germinativum (basal layer) ([@b0845]). The outermost layer or horny layer SC (10--20 μm) has been referred to as "a brick wall-like structure of corneocytes as "bricks" in a matrix of intercellular lipids, with desmosomes acting as molecular rivets between the corneocytes" ([@b0045]). Under the SC layer is the viable epidermis layer, which contains the keratinocytes and pigment-producing cells, the melanocytes. This layer is responsible for most drug-related actions, such as drug binding, metabolism, active transport, and surveillance. This layer also contains specialized cells such as the Merkel and Langerhans cells ([@b0530]).

The second skin layer is the dermis (3--100 mm), which follows the viable epidermis layer. Here, the skin is made up a more complex mix of cells with different functions such as connective tissue, vascular tissue, lymphatic vessel network, sweat and sebum glands, hair follicles and macrophages ([@b0690]). This layer not only functions as a host layer for the network of functional tissue but also provides structural support in the skin due to the presence of fibroblasts ([@b0690]).

The third skin layer, the hypodermis (subcutis) follows the dermis layer, which contains loose connective tissue. The major cells found here are the adipocytes, which function in fat storage for use in body temperature regulation during cold as well as cushioning against outside insults ([@b0675]). The transfer of molecules via the skin follows an intricate set of steps, involving a number of mechanisms; the intracellular absorption of the molecule passes through the keratin-packed corneocytes by partitioning into and out of the cell membrane; the intercellular absorption where the molecule passes around the corneocytes in the lipid-rich extracellular regions; and appendageal absorption where the molecule moves through the shunts of hair follicles, sweat glands, and sebaceous glands ([@b0730]).

3. Transdermal drug delivery (TDD) {#s0015}
==================================

Transdermal delivery is gaining interest as an option for drug administration. The drug reaches the systemic circulation through the skin without losing the drug during reaching its target, enhance the bioavailability, improving sustained drug release, minimizing undesirable side effects, and improving physiological and pharmacological response ([@b0480], [@b0615]). For instance, in testosterone replacement studies, transdermal delivery overcomes the issues associated with oral and intramuscular delivery, it bypasses the hepatic first-pass after oral administration, and thus reduce the required dose. Besides, it eliminates the need for recurring injections and a higher concentration of testosterone in the blood ([@b0250], [@b0715]). Nevertheless, the delivery of drugs via the transdermal administration route is highly affected by the chemical properties of drugs, which affects absorption through the SC. Hence, few drugs can be delivered in significantly therapeutic amounts via this route ([@b0520]).

The drugs applied through transdermal drug delivery system needs to take a tortuous route to bypass through consecutive skin layers containing both aqueous and lipid domains and reach the systemic circulation ([@b0485], [@b0245]). The drug molecule needs to have ideal properties to pass through SC layer; the molecular weight must be less than 600 Da, the value of Log P between 1 and 3, High, but balanced, SC/vehicle partition coefficient, and Low melting point, correlating with good solubility, as predicted by ideal solubility theory ([@b0835]). Olanzapine is one of the drugs that have required physicochemical properties for effective transdermal drug delivery. It is lipophilic (log P 2.8), has a low molecular weight of 312.4 and a low melting point (195 °C). The poor bioavailability of olanzapine orally and susceptibility to loss during delivery means that only 40% of the actual dose remains before entering the circulation system. Together, these characteristics make olanzapine a good candidate for delivery via transdermal drug patches ([@b0025], [@b0285]). Obviously, many medications are unable to follow these stringent requirements for transdermal delivery ([@b0180], [@b0185]).

There are three generations of transdermal drug delivery, as illustrated in [Fig. 2](#f0010){ref-type="fig"} . In the first generation, the systems used for transdermal drug delivery was patches, the drug candidate that is appropriate for patch formulation is extremely limited and has to fall into optimal ranges of molecular weight, hydrophilicity and effectiveness at low dosage ([@b0205]). The second generation of TDDS was implemented with a skin permeability enhancement technique to extend its application in transdermal drug delivery. Improvement methods included iontophoresis, chemical enhancers and non-cavitational ultrasound. Nevertheless, these methods struggle to protect the deeper tissues from any physiological harm and increase the distribution of drug molecules through SC ([@b0430]). In the third generation, novel chemical enhancers, electroporation, cavitational ultrasound, microneedles, thermal ablation and microdermabrasion were introduced, these techniques allowed the biotherapeutics and large molecules to better penetrate the outer corneum layer, resulting in increased efficacy of transdermal delivery in human clinical trials ([@b0555]). However, the techniques used abrasion methods, lasers and heat and exposure to radiofrequency, which harmed the skin, caused discomfort in patients and resulted in the application of the drug and treatment of side effects. Such limitations can be solved by using micrometer size needles called microneedles ([@b0050]).Fig. 2Generations of transdermal drug delivery.

MNs technology has grown in the last 15 years, permitting drugs to cross the outer corneum layer by puncturing the skin and creation of micro-channels in the outer corneum using micron needles. Compared to other transdermal delivery methods, microneedles are able to deliver molecules of larger sizes without disturbing the nerve endings in the skin, hence minimizing or altogether avoiding pain experienced by patients. Furthermore, microneedles can be used in both solid and liquid preparations according to the required specifications of the disease ([@b0110]). The MNs is promising for the future of TDD to facilitate the delivery of drugs with large molecular weight and low lipophilicity, such as proteins, peptides and vaccines, as well as drugs with poor effectiveness at low doses ([@b0785], [@b0835]).

3.1. Microneedle drug delivery system {#s0020}
-------------------------------------

Microneedle (MN) technology employs microscopic needles to deliver drugs across the SC layer into the underlying layers with minimal invasiveness. The microneedles used in these delivery systems differ in length; some are just a few micrometers long but can go up to 2000 μm ([@b0740]). The short length of MN allows penetration of the SC without touching the nerves in the underlying layers of the skin ([@b0610]). The use of MNs is preferred over conventional drug delivery methods due to its simple delivery mechanism, pain-free, and minimally invasive devices that offer the simplicity of using transdermal while delivering the effectiveness of invasive needles and syringe ([@b0560]). Unlike conventional methods, MNs do not require specialized skills or personnel, as they are designed for self-administration by patients. Furthermore, MNs are designed for single-uses; this minimizes the potential for cross-contamination of the drugs ([@b0475]).

MNs are categorized into five different groups according to the design: solid, hollow, coated, dissolving, and hydrogel-forming microneedles, as illustrated in [Fig. 3](#f0015){ref-type="fig"} . Solid MN delivery consists of two steps and is known as the "poke and patch" approach; first, holes are introduced into the skin using MN arrays; secondly, a conventional drug formulation is delivered via transdermal drug patch ([@b0575], [@b0740]). Coated MNs follow the "coat and patch" approach; here, a drug formulation is coated onto the microneedles prior to application into the skin. Penetration into the skin allows the coating to dissolve; thereafter, the drug is deposited into the skin. In the hollow microneedles approach, the drug is filled into the hollow space in the tip of the microneedle, which is directly deposited into the epidermis or upper dermis layer of the skin upon insertion. In simple terms, this can be described as "poke and flow" ([@b0580]). Dissolving microneedle is made mainly from dissolving or biodegradable polymers and allows for the simple one-step application process, and hydrogel-forming microneedles which absorb water in large quantities into their polymeric network, resulting in swelling ([@b0785]). The mechanism of dissolving and hydrogel-forming MN drug delivery is termed as poke and release; both strategies eliminate the need to use special measures for discarding of the needle and the risk of inadvertent reuse of the MN ([@b0020], [@b0760]).Fig. 3The drug delivery mechanism of solid microneedle (solid MN), coated microneedle (coated MN), hollow microneedle (hollow MN), dissolving microneedle (dissolving MN) and hydrogel-forming microneedle (hydrogel-forming MN).

The material used for microneedle can be metal, polymer, glass, and silicon ([@b0060]). Metal, glass, silicon and ceramics are used in the manufacture of MNs. They are rigid, which allows skin penetration, but brittle, risking breakage inside the skin layers, causing pain, swelling and possibly granulomas. The rigid but brittle properties of these materials have been likened to sea urchin thorns made of mineral calcite. As accidents and issues in the administration of the MNs are inescapable, the best materials for MNs should be biodegradable and biocompatible, to avoid complications that occur from accidents such as when the MN tip breaks inside the first few layers of the skin ([@b0145]).

Design and manufacture of the MN focus on the shape and geometry to ensure that the needles are able to function optimally. The strength of the needle allows it to keep intact during penetration and delivery, while tip geometry is crucial to evade the nerve endings. MNs made of metals are able to withhold the force of penetrating the skin, but polymer MNs requires additional strengthening. The MNs need to be able to break the skin barrier without breaking or bending ([@b0865]). MNs can be anywhere between 25 and 2500 μm long, 50 to 250 μm wide, and their tips measure 1 to 25 μm in diameter ([@b0665], [@b0865]). The overall shape of the microneedle and the geometry of the tip has been used to classify microneedles; into rectangular, pyramidal, cylindrical, conical, or quadrangular with varying dimensions ([@b0665]).

3.2. Polymeric microneedles {#s0025}
---------------------------

Silicon is brittle and does not metabolize in the body; hence the use of other materials such as polymers favoured the production of microneedles. Polymers are preferred due to their inexpensive cost, biocompatibility, biodegradability, hygienic use, swelling and dissolving abilities ([@b0195], [@b0280]). Their degradation *in vivo* in the presence or absence of degrading enzymes yields non- toxic by-products. This property reduces the possibility of infection in the body ([@b0030]). Polymers are used predominantly in the manufacture of dissolving and hydrogel-forming MNs arrays ([@b0160], [@b0500]). Nevertheless, there are few studies using polymers for the production of coated, solid, and hollow MNs which attributed to the weakness of the polymer mechanical strength that is likely to fail during insertion ([@b0015]).

The polymeric MNs can be classified according to materials, formulations, construction of MNs and *in vivo* performance ([@b0835]); In solid polymer microneedles, the drug is not encapsulated in solid microneedles, and they are effective in generating holes through the SC ([@b0445]). Likewise, hollow microneedles act as external drug reservoir applied after creating microchannels in the skin ([@b0865]). Also, the drug formulation and polymers can be coated onto MNs using various coating methods such as dip-coating, casting deposition techniques, spray drying, and Inkjet printing ([@b0095], [@b0465], [@b0505], [@b0745]). However, the drug loading in coating layers of MNs is restricted due to the limited MN quantity ([@b0090]).

Dissolving MNs polymers are considered the most effective approach and have many applications; the drug incorporated into dissolvable or degradable polymeric MNs ([@b0835]). As compared to coating MNs, this MNs can significantly enhance the drug loading capacity by encapsulating drug molecules into the whole needle instead of coating on its external surface ([@b0650]). The release of drugs depends mainly on dissolving and degradations proprieties of polymer in the skin. Dissolvable MNs can be used to deliver and release molecules quickly. This strategy ensures that drugs are delivered to specific targets and taken up immediately, which is plausible for short term applications ([@b0215], [@b0790]).

On the other hand, MNs made of biodegradable polymers are dissolve over a period of time find interesting applications in prolonged/sustained delivery of drugs, the choice of biodegradable polymers is critical to manipulate and control the sustained release profile of drugs according to their degradation rates ([@b0735], [@b0780]). Additionally, the hydrogel-forming MNs prepared mainly from polymer that absorbs interstitial skin fluids and swells to form a hydrogel mass to regulate the release of the drug depending on the crosslinking strength of the hydrogel network. This permits slow drug release over a period of several days ([@b0065], [@b0075]).

The advanced approach of MNs combining between polymer and micro- and nano-particles formulations for the delivery of many different types of therapeutics across the skin ([@b0835]). For instance, the microparticle insulin embedded in MNs arrays provides a greater hypoglycaemic effect comparing with MNs insulin arrays only ([@b0395]). Furthermore, the recent developments focused on the fabrication of smart MNs (bioresponsive) to control drug delivery. In contrast to dissolving and biodegradable MNs, the bioresponsive MNs release the drug smartly according to the change of the physiological signals that achieved by loading of drugs in bioresponsive polymers or encapsulation of drugs in physiological signal sensitive micro- or nanoparticles such as ([@b0200]) pH-responsive drug release ([@b0750]), surface activation of nanoparticle that commonly used in cancer treatment ([@b0100], [@b0660]), glucose that incorporated with insulin in the tips of MNs array ([@b0855]), reactive oxygen species (ROS)-responsive microneedle (MN) patch for anti-acne therapy ([@b0875], [@b0880]), and enzymes that triggered or suppress drug release through the inactivity or overexpression of enzymes ([@b0685], [@b0860]).

Smart MNs offers opportunities to provide controlled drug delivery based on physiological responses for certain diseases conditions ([@b0330]). For instance, [@b0870] employed glucose-responsive nanoparticles to encapsulate rosiglitazone as the browning agents that further combined into the polymer MNs array. The pH-sensitive nanoparticle gradually degraded under the physiological glucose condition to release the browning agents into the subcutaneous adipocytes in a sustained manner that leads to increases whole-body energy expenditure and improves type-2 diabetes in a diet-induced obesity mouse model ([@b0870]).

The most frequently used matrix materials for dissolving polymer MNs are sodium hyaluronate, that is naturally present in the skin ([@b0275], [@b0495]), sodium carboxymethylcellulose ([@b0490]), poly(vinylalcohol) (PVA) ([@b0565]), poly(vinylpyrrolidone) (PVP) ([@b0705]), methylvinylether-co-maleic anhydride (PMVE/MA) (Gantrez AN-139®) ([@b0180]), dextran ([@b0305]), sodium chondroitin sulphate ([@b0300]), hydroxypropyl cellulose (HPC) ([@b0035]), carboxymethyl cellulose (CMC) ([@b0590]), hydroxypropyl methylcellulose (HPMC) ([@b0260]), sodium alginate ([@b0880]), and hyaluronic acid (HA) ([@b0350]). Meanwhile, other biodegradable polymers used in MN fabrication such as polylactic acid ([@b0540]), chitosan ([@b0710]), polyglycolic acid, or poly(lactide-co-glycolide) (PLGA) ([@b0265]) degrade in the skin post-application. In addition to, bioresponsive polymers such as cross-linked methacrylated HA (MeHA) ([@b0855]), cross-linked polyvinyl alcohol (PVA) ([@b0805]), and cross-linked alginate (W. [@b0105]).

Ideal polymeric microneedles should be biocompatible, non-immunogenic, mechanically strong, and able to carry large complex drugs without damage ([@b0200]). Thus the development of polymeric microneedles must consider the type of polymer used, manufacturing process, and design of the MN tip length, width and shape ([@b0790]). Each polymer in studies provides own characterisation in term of strength permeation capability, and drug release either immediate or sustained release.

The major challenge associated with polymeric MNs is the penetration of MNS through the skin layer. Mostly, the mechanical strength is weaker in water-soluble polymers compared to non-dissolving materials such as silicon or metal, and drug encapsulation may further compromise the strength of the MNs ([@b0170], [@b0780]). Mechanical Strength, elastic modulus and fracture toughness of polymer MNs are important; it is reflecting the insertion ability of polymer-based microneedle arrays. Stronger needles will be able to withstand forces without bending and breakage ([@b0315]). Therefore, researchers can combine two or more polymers and additional materials to improve the mechanical strength of MNs ([@b0775]). Besides, target tissue for MN either transdermal or non-transdermal must be considered during select of MNs polymers. Non-transdermal targets such as eye tissue, vascular tissues, and the digestive system are often required MNs that are bendable and simple to use surgically, the right balance of strength and flexibility must be considered when targeting soft tissues that may not be able to handle the pressure of high- strength MN insertion ([@b0400]). Another factor meaningful to consider is environmental humidity because higher moisture levels weakened the MNs strength depend on the polymer used and the level of humidity ([@b0795]). Furthermore, the active ingredient added into the polymer MNs patch might enhance the mechanical strength but sometimes increase of drug loading led to a decrease in MN mechanical strength ([@b0275], [@b0600]). Additionally, the mechanical strength of MNs could diminish in case the drug distributed in the needles and baseplates of MNs arrays that indicated by cracking of the baseplate following mechanical evaluation whereas localization the drug in needles not just solve the mechanical strength issue but also results in a reduction in drug wastage as well ([@b0600], [@b0625]).

Microneedle design is an essential aspect determining the effectiveness of the MN form and function ([@b0155], [@b0790]). Microneedles are organized as arrays of structures either in cone or pyramid form, which function to pierce the human skin to deliver drugs ([@b0725]). The material used in MN fabrication is the most important factor in design, as it determines the mechanical strength and drug release properties of the MN. Other factors that need to be considered include the density of the material, height of the microneedle, and diameter width of the tip and base of the microneedle ([@b0450]). Microneedles are arrays of cone- or pyramid-shaped structures formed with different materials, generally ranging from 250 to 2000 mm in height could cross the human skin barrier to deliver targeted drug molecules ([@b0725]). Several researchers have varied MN length, width, thickness and tip size to optimize penetration ([@b0830]), a sensation of pain compared to conventional needle injection, and effectiveness of drug delivery ([@b0460]), using different designs/geometries of MNs could lead to maximizing the dose efficiency of the drugs ([@b0600], [@b0830]).

Polymer MNs are commonly produced using moulding techniques, this method allows for upscaling production, it carries limitations as it usually involves multiple time-consuming steps such as master preparation, mould fabrication, plasticisation of thermoplastic polymers above their glass transition temperature, thus thermo-liable drugs cannot be used ([@b0810]). The researchers solve the issue of thermo-liable drugs by filling the drug and polymer solutions into the mould under vacuum or pressure, and drying under ambient conditions, centrifugation or pressure ([@b0280], [@b0310], [@b0695], [@b0800]). 3D printing has also been described recently in published reports as an alternative manufacture technique for MNs ([@b0065]). The fabrication process for microneedles should take into consideration factors such as the sharpness of the MNs tips, take place at ambient temperatures, absence of organic solvents, and preservation of the bioactivity of the loaded drug molecules ([@b0700]).

Polymer MNs are able to improve the flux of the molecules ranging from small hydrophilic molecules such as alendronate to macromolecules, including heparins, insulin and vaccines ([@b0020], [@b0785]) as illustrated in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"} . Several studies have shown the effectiveness of MNs array for the transdermal delivery of low molecular weight drugs, biological therapies and vaccines ([@b0235]). Biotherapeutics are more complex and expensive than a small molecule pharmaceutical product; they produce through a biological process from living organisms rather than chemical synthesis including biotechnology methods ([@b0570]). Opposite to small molecule, the macromolecules and proteins are too large to diffuse into blood capillaries but are able to enter into the lymphatic vessel ([@b0080]).Table 1Polymeric microneedle for delivering small and macromolecules.CompoundsPolymerType of MNsFabrication methodGeometry of MNsMain outcomeReferenceSulforhodamine B•Polylactic acid PLA (solid MNs).•Polyvinyl alcohol (PVA) and sucrose (coating solution).Coated MNs•Moulding (solid MNs)•Dip-coating process (coating)(5 × 5 arrays, 550, 650, and 750 μm height)The MNs height and viscosity of coating solution has a significant impact on the drug loading and drug delivery efficiency. The drug loading may enhance by increasing the MNs height and viscosity of coating solution. However, once the viscosity of the coating solution increased, the sharpness of MNs reduced that leads to difficulties in skin penetration and low drug delivery efficiency.([@b0090])Bleomycin•Poly-lactic-co-glycolic acid (PLGA) and poly-lactic-acid (L-PLA) (solid MNs).•Carboxymethyl-cellulose sodium salt (CMC) (coating solution).Coated MNs•Moulding (solid MNs)•Dip-coating process (coating)Pyramid shapeL-PLA MNs were selected for pre-coated microneedle as they had sufficient mechanical strength for skin penetration regardless of body. Moreover, bleomycin-coated MNs can deliver more concentrated drug dose compared with intralesional injection.([@b0425])GentamicinSodium hyaluronate and poly (vinylpyrrolidone).Dissolving microneedleMouldingPyramid-shaped (19 × 19 needles 500 μm in height)The mechanical strength of polymer microneedles was strong enough to penetrate the skin layer. Besides, theses polymer MNs provides sustained release delivery of the drug.([@b0230])Vitamin D3 (VD3) nano-microparticlesPoly (lactic-co-glycolic acid) (PLGA) to prepared VD3 nano-microparticles and polyvinylpyrrolidone (PVP)Dissolving MNs(including nano and microparticles)Laser engineered micromouldsConical (19 × 19 and 12 × 12 arrays) and pyramidal (14 × 14) shaped (600 μm hight and 300 μm widths at base).The polymer MNs shows good mechanical strength and safely inserted to the skin. Moreover, prepared VD3 as nanoparticle provide immediate release profile of the drug.([@b0775]).Fluorescein sodium and fluorescein isothiocyanate--dextransPolyvinylpyrrolidone (PVP)Dissolving MNsLaser-engineered silicone micromouldsConical shaped (3 × 3 arrays, 800 μm tall, 300 μm wide at the base, and 50 μm between needles)Polymer MNs can be also used to deliver the drug to the eye and is considered an effective method in enhancing ocular delivery of both small and macromolecules.([@b0720]).DonepezilPoly(vinylpyrrolidone) or poly (methyl vinyl ether co-maleic anhydride/acid) (Gantrez®) polymersHydrogel-forming MNsMouldingConical shape (600 μm long, 300 μm wide and 150 μm between needles)The type of polymer used to prepare MNs has impact on permeation of MNs and dissolution rate. By comparison between PVP and Gantrez®, it was found that permeation through the skin was greater in Gantrez®, while PVP MNs had a higher dissolution rate.([@b0335])Doxorubicin (DOX)Gelatin methacryloyl (GelMA)Bioresponsive and biodegradable MNs.Micro transfer moulding and cross-linked by UV irradiation(11 × 11 array, 600 μm in Height, 300 μm base width)The crosslinking degree of the polymer (GelMA) has an influence on drug release behaviour of MNs. Zero polymer crosslinking result in release over 80% of DOX in 30 min while cross-linking with UV irradiation for 1 min leads to about 50% release of DOX in the first 2 h, followed by slow release over 22 h of the remaining 20%.([@b0455])Sulfonhodamine B (SRB)Hyaluronic acid (HA) andPolyvinyl alcohol (PVA)Dissolving MNsCasting(10 × 10 MN array, 600 μm long, 300 μm wide, and 600 μm between needles)The drug distribution in the MNs plays a major role in the fabrication and performance of MNs. By comparison between HA and PVA MNs; the drug diffusion in PVA MNs is limited and most of the drug are concentrated in the needle tip. On the other hand, HA MNs show poor control of the drug diffusion and SRB molecules was diffuse into the base of MNs. As a result, the PVA based MNs would be better for MNs fabrication while HA MNs face a great challenge to achieve ideal the controlled distribution of drugs.([@b0210])Diclofenac sodiumChitosan and PVPHydrogel-forming MNsMoulding(2.4 mm long, between 780 and 800 μm in base diameter, and 210 μm in tip diameter)Combine chitosan and PVA for preparation of MNs leads to the improved mechanical strength of MNs and enabled a sustained drug release profile.([@b0150])Antifilariasis drugs (Diethylcarbamazine Albendazole, and Doxycycline)poly(vinyl alcohol) (PVA) and Poly(vinylpyrrolidone) (PVP)Dissolving MNs (including solid lipid nanoparticles)MouldingPyramidal shape (19 × 19 needles; 500 μm height and 300 μm width at base and 300 μm interspacing).MNs prepared using PVP and PVA polymers separately, PVP exhibited poor mechanical properties and PVA show adequate mechanical strength. The combination of PVP and PVA could potentially increase the mechanical strength of MNs. Besides, this delivery approach provides effective therapy for lymphatic filariasis.([@b0600])Table 2Polymeric microneedle for delivering of biotherapeutics.CompoundsPolymerType of MNsFabrication methodGeometry of MNsMain outcomeReferenceInsulinPolylactic acid (PLA)Solid MNsMouldingMNs with different with 600, μm heights.The pretreatment of skin with polymer solid MNs produces microchannels in the skin that mediated insulin delivery in a slow manner to lower the blood glucose level as drug molecules would be difficult to diffuse rapidly into the skin across the micro-holes whereas the subcutaneous injection of insulin can reduce the blood glucose quickly.([@b0445])InsulinAlginate and hyaluronateDissolving MNsMouldingPyramids shaped (10 × 10 array, tip width \~10 μm, height \~700 μm and the space between each two MNs is \~600 μm)Polymer MNs prepared using alginate and hyaluronate displayed good mechanical strength as well as good degradation rate for release of insulin. Also, the relative pharmacological availability of insulin MNs was close to the subcutaneous injection suggesting the potential application of MNs for diabetes treatment.([@b0850])Lysozyme (LYS)Carboxymethyl cellulose (CMC), polyvinylpyrrolidone (PVP) and hyaluronic acid (HA).Dissolving MNsDroplet-born air blowing methodNeedle with micro-dimensions and a sharp tip.The stability of lysozyme (LYS) as a model protein was preserved in the polymer MNs by keeps the fabrication process at low temperature, and mild drying condition. Besides, using specific polymer concentration and add protein stabilizer. These findings highlight the importance of optimizing polymer MNs fabrication parameters to maintain the activity of polymer MNs encapsulated proteins or antigens.([@b0385])Parathyroid hormone (PTH)Hyaluronic acid (HA)Dissolving MNsMicro-mouldingMNs were approximately 800 μm long, 160 μm in base diameter, 40 μm tip diameter, and spaced 600 μm wide between each row of needles.The polymer MNs of PTH show excellent performance for transdermal drug delivery in a rat model of osteoporosis with relative bioavailability reaches to 100 ± 4% compared to normal injection. These findings indicate that the low absorption issue associated with oral dosage form or painful frequent injections could be replaced with self-administration of dissolving MNs.([@b0545])Monoclonal immunoglobulin G (IgG)Hyaluronic acid (HA)Dissolving MNsMouldingMNs (4 × 4) array and the length was 300 μm.The polymer MNs of (IgG) using HA provide rapid non-invasive intradermal protein delivery as well as maintain the stability of protein.([@b0525])DNA vaccine for cervical cancerPolyvinylpyrrolidone (PVP)Dissolving MNs (including cationic nanoparticles)Micro-mouldingMNs (19x19) needles were 600 μm long, 300 μm wide at the base and 300 μm between needles.NPs have sufficient cationic charge to prevent aggregation in order to bind to the negatively charged cancer cell membrane. In general, the vaccine nanoparticles loaded in MNs trigger a robust antigen-specific humoral immune response comparable and even superior to intramuscular injections.([@b0010])Transcribed messenger RNA (mRNA) based cancer vaccinationlow molecular weight Polyvinylpyrrolidone (PVP)Dissolving MNsMicro-mouldingPyramidal shapePolymer MNs triggered more cellular and humoral immune responses comparing with subcutaneous injection.([@b0375])DNA vaccine against antigens of prostate cancer stem cellsPolyvinylpyrrolidone (PVP)Dissolving MNs (including cationic nanoparticles)Moulding--Vaccine loaded in cationic nanoparticle and integrated in polymer MNs is effectively triggered immune response towards endogenous prostate cancer and demonstrated anti-tumour activity in both prophylactic and therapeutic.([@b0125])Anti-vascular endothelial growth factor (VEGF) aptamerPolyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP)Dissolving MNsMouldingPyramidal shape consisted of 100 microneedle array (10 × 10) with a 600 μm, height, 200 μm, base, andb500 μm, tip-to-tip distance.Polymer MNs loaded with aptamer shows high mechanical strength and immediately released to inhibit protein-mediated cell growth. It is interesting prospects as a treatment for diseases caused by protein overexpression.([@b0135])STAT3 siRNA for melanoma treatmentDextran 40, polyvinylpyrrolidone (PVP 17), and sodium hyaluronate (HA)Dissolving MNsMouldingPyramidal shape comprised of 144 (12 × 12) needles 650 μm long, 300 μm wide, 20 μm wide in the tip radius and 300 μm spaced between the arraysThe use of polymer MNs for delivery of STAT3 siRNA shows good initial results for the treatment of skin melanoma with effective inhibition rates and minimal adverse effects.([@b0585])Dermatophagoides farina (D. farinae) extract (Allergen-specific immunotherapy)Sodium hyaluronate (HA)Dissolving MNsDroplet-born air blowing (DAB)Microneedle array consisted of 76 needles with 0.25 mm needle length.Polymer MNs were able to immunize against allergic disease at low dose by activating dendritic cells in the skin without significant side effects.([@b0360])Bovine serum albumin (BSA),Poly (vinyl alcohol) (PVA) and poly (lactic-co-glycolic acid) (PLGA)Biodegradable MNsDual-nozzle spray delivery and mouldingPyramidal shape microneedles (10 × 10) arrays 600 μm long and 300 µm wide,Encapsulation of labile substances (BSA) in polymer MNs using dual-nozzle spray process enhanced the drug stability via minimizing unfavourable processing conditions such as the emulsification process.([@b0355])Rhodamine B (RhB) indocyanine green (ICG) and doxorubicin (DOX)Sucrose/ Poly-(ethylene glycol) diacrylate (PEGDA) at weight ratios 1:20, 2:20, and 3:20Hydrogel- forming MNsMoulding and UV-induced polymerizationMicroneedle patch consisted of (15 × 15) needles.PEGDA-based microneedles triggered by polymer swelling under the physiological condition that provide sustained release while the higher sucrose content contributed to a more rapid drug dissolution in the hydrogel.([@b0220])Gene therapy (p53 DNA and IR820) for cancer treatmentSodium hyaluronate (HA)Dissolving MNsCasting methodMN patch (5 × 5 array) 904 ± 8 mm long, 8 ± 2 mm wide tip diameter, 313 ± 12 mm wide base and 1094 ± 26 mm measured between tipsThe polymer MNs is capable to deliver a gene and photothermal therapies simultaneously and provide a synergistic strategy for cancer treatments.([@b0820])Diphtheria toxoid (DT) vaccineSodium hyaluronate, (HA)Dissolving MNsMouldingMN arrays (4 × 4 needles)The immunization using polymer dissolving MNs shows a higher immune response comparing with hollow MNs. Furthermore, dissolving MNs loading unadjuvanted (DT) provide comparable immune responses after prime immunization comparing with subcutaneous injected DT-AlPO4.([@b0435])Recombinant coronavirus vaccinesCarboxymethyl cellulose (CMC)Dissolving MNsCasting --mouldingMicroneedles were a 750 µm long, 225 µm wide, and 30° in apex angleCoronavirus-S1subunit vaccines loaded in polymer MNs trigger potent antigen-specific antibody responses beginning 2 weeks after immunization.([@b0345])vascular endothelial growth factor (VEGF)Chitosan and (N-isopropylacrylamide) (pNIPAM)Bioresponsive MNsMouldingConical shape (20 × 20 MN array, 600 μm height with 5 μm tip diameter and 300 μm base diameter)The temperature-responsive pNIPAM provides control drug release drugs via temperature rising associated with inflammation response at the site of the wound. Besides, chitosan MNs possesses a natural antibacterial property that promotes inflammatory inhibition, collagen deposition, angiogenesis, and tissue regeneration during wound closure.([@b0115]).

The biotherapeutics classified to different types including vaccine-based products, blood component, allergenic, gene therapy, human tissue, proteins and peptides ([@b0570]). These biotherapeutics are normally delivered via needle injection due to their poor properties. However, it is well documented that patient compliance with this route is poor due to the pain encountered and potential for contamination and infection ([@b0825]). The introduction of MNs that are able to penetrate the skin at constant depths allows for the introduction of macromolecules to their targets in a rapid and effective manner while avoiding the pain associated with injections due to the absence of contact with nerve endings in the deeper layers of the skin ([@b0835]). Beside, delivers of biotherapeutics such as vaccines through MNs inducing a more potent long-lasting immune response with less vaccine comparing with subcutaneous or intramuscular injection as the vaccines would be closer to antigen-presenting cells present in human skin as well as the biotherapeutics usually do not need to be administered in large doses that means the dose limitations associated with coated or dissolving microneedle systems are not a concern ([@b0410]). Furthermore, improvements in vaccine stabilization technologies, it may be possible to create microneedle vaccines that avoid the need for refrigeration ([@b0120]). Altogether, this suggests that microneedle vaccines should be able to be stockpiled under much less costly conditions and possibly at a greater number of locations.

4. Evaluation of drug-loaded polymer microneedles {#s0030}
=================================================

Designing polymer microneedles, the materials and manufacturing process are important parameters to consider; effective MNs for drug delivery depends on the mechanical strength, skin permeation, and release kinetics that subsequently affect drug delivery as simplifying in [Fig. 4](#f0020){ref-type="fig"} . The morphology and dimensions of MNs including the tip radius, heights, widths, lengths and interspacing of the polymer MNs can be observed using stereomicroscopy, transmission electron microscopy (TEM) or scanning electron microscopy (SEM). The amount of drug encapsulated in the MN is affected by the structural properties of the MN, which is determined by the type and stability of the drug of interest ([@b0420]). The mechanical strength is commonly investigated by using a Texture Analyser in compression mode ([@b0780]) or motorized force measurement test stand ([@b0255]). For fracture testing, the MN arrays are subjected to a microscope observation before and after the tests to determine differences in height.Fig. 4The main procedure to evaluate drug-loaded polymer microneedle.

The shape of the microneedle is an important aspect of MN design; it decides how much force can be applied to the MN before the needle breaks. The diameter and angle of the tip, as well as the height and base measurements of the MN, determine safe and reliable insertion of the microneedle into the skin ([@b0040]). Generally, a smaller tip diameter, smaller tip angle, as well as a high ratio of height to base width result in successful needle insertion ([@b0325]). Most incomplete insertions occurred due to skin distortions when the length of MNs is short, or aspect ratio is small ([@b0130]). This situation can be avoided by increasing the length of the needle or manipulating the forces used during manual needle insertion. The force applied during insertion can also be controlled by using special MN applicators that decrease skin distortion and standardize the amount of applied pressure ([@b0140], [@b0240]). The skin on different locations of the body have different degrees of distortion; hence the MN design and insertion methods should be individually tailored to achieve successful MN application in these locations ([@b0325]).

MNs are applied to the skin surface and pierce the epidermis, creating microscopic holes through which drugs diffuse to the dermal microcirculation. The success of microneedle penetration can be assessed using either parafilm or carefully prepared porcine skin; this porcine skin has close physical properties to human skin, it can be used as a good human skin model ([@b0085], [@b0405], [@b0780]). The holes produce by applying MNs in the parafilm, or porcine skin can be visually observed after removal of MNs using methylene blue staining, and the number the blue dots of methylene blue dividing with the number of microneedles on the array, the percentage of successful skin penetration was obtained ([@b0815]). The "penetration success rate" is related to the number of microneedles that penetrate the skin. A 100% success rate indicates that all MN arrays will observe in the skin ([@b0165]). Generally, parameters such as the tip diameter, base width, length of the microneedle, type of microneedle and its mechanical strength play a critical role in the dimensions of the created microchannel ([@b0320]).

The microchannel dimensions created by MN can be estimated by histology examination ([@b0670]). However, the sample preparation for histological examination may alter skin structure during the freezing and sectioning steps that lead to inaccurate assessment of the microneedle penetration into the skin ([@b0450], [@b0565]). Thus, a real-time non-invasive method optical coherence tomography (OCT) can be used for skin characterization ([@b0175]). In addition, the measurement of transepidermal water loss (TEWL) is usually carried to evaluate the effect of microneedle application on the skin barrier integrity ([@b0650]). The common side effect during microneedle insertion includes mild and transient erythema at the site of application that can simply be observed by dermatoscopic or stereo microscopy ([@b0885]). Besides, the time required for skin recovery to its original state must be noted to evaluate the skin tolerability towards microneedle application ([@b0650]).

The quantity of drug release through the skin or drug encapsulation in MNs can be assessed using Franz diffusion with the neonatal porcine skin attached facing upwards in the donor compartment of the diffusion cell, and phosphate-buffered saline at pH 7.4 and temperature at 37 °C in the receiver compartment of the cell. The MNs array is applied to the test 'skin' and at set time intervals, samples are taken from the sampling arms of the cell and evaluated. Likewise, the MNs are placed inside a beaker or glass vial phosphate-buffered saline (PBS) or any other suitable buffer at pH 7.4 at 37 °C for *in vitro* drug release, and samples are taken at set intervals, samples are taken at set intervals to determine drug concentrations ([@b0230]). The drug release also can be evaluated using *in vivo* animal model; appropriate rat or mice are commonly employed. The anaesthetized animals' fur is removed, then the underlying skin is pierced firmly using the MN patch. Upon skin penetration, other parameters related to the efficacy of MN can be evaluated such as the MN strength, penetration power, and irritation ([@b0655]).

Most MN studies are performed *in vivo* in animal models or *ex vivo* on human skin. However, it has been pointed out that the structure and immune response in the animal model differs significantly from humans. Furthermore, the biochemical properties of human skin *ex vivo* are different compared to intact human skin ([@b0130]). Hence, in moving towards clinical trials, human tests need to be included in studies for the results to accurately represent MN function in humans ([@b0030]).

5. Scale-up and manufacturing considerations {#s0035}
============================================

The greater acceptance of microneedle-based devices in patients has encouraged an increase in market entry, decreased the cost of innovation and accelerated market growth of MNs. Developments in the field are saturated, as evidenced by the increased number of academic publications and patents on MNs annually. Continuous efforts to transfer scientific research into the clinical application has been ongoing for the past 20 years, with research groups now taking initial commercializing steps ([@b0145]). This jump from experimental research to an initial commercialization stage is evidenced in the number of concluded clinical trials in the USA, as can be accessed via [[https://clinicaltrials.gov/]{.ul}](https://clinicaltrials.gov/){#ir005}. The global transdermal drug delivery market is estimated to be worth approximately \$95.57 billion by 2025 (Businesswire). Currently, there are no MN-containing drug or protein products in the market; only MN-based devices used to administer drug are available ([@b0080], [@b0630]), Some of MNs devices presented in [Table 3](#t0015){ref-type="table"} .Table 3Currently marketed microneedle devices for therapeutic use.Serial no.CompanyMarketed productFeaturesReference1Valeritas Inc., Bridgewater, NJ, USAV-GoA disposable insulin delivery device([@b0365], [@b0620]).2Zosano pharma Inc., United StatesAdhesive Dermally Applied Microarray (ADAM)Utilizing for delivery of zolmitriptan([@b0340], [@b0680])3Sanofi Pasteur, Swiftwater, PA, USAFluzone® Intradermal QuadrivalentUsed for delivery of the seasonal influenza vaccine([@b0755])4DebiojectDebioJect™This MN can be connected to any standard syringes to ensure the full penetration of the microneedle into the skin([@b0765])5Becton Dickinson, Franklin Lakes, NJ, USABD Soluvia™The first hollow microneedle product approved for vaccination([@b0055], [@b0185])6NanoPass TechnologiesMicronJet™It is a single-use, microneedle-based device for intradermal delivery of drugs, proteins and vaccines([@b0185], [@b0295])7Nano BioSciencesAdminPatch® Microneedle ArraysThis MN allows continuous delivery of drugs by laminated the transdermal patch on the back surface of the microneedles([@b0185])8DermaIndia, Chennai, IndiaDermaroller® microneedlerollersThis MN helps to treat some skin conditions([@b0550])

The main focus of MN clinical trials up to this point has been to overcome the skin barrier for initial penetration, improving delivery, assessing immunologic reactions to large molecular drugs, investigating sensory reactions in the skin and general patient attitude towards MN use ([@b0535]). Recent findings in MN research report the poor biocompatibility of silicon for use in MNs, as well as the possibility of abuse of MNs that do not break off/ dissolve after administration to the patient. As a result, current investigations are directed towards the preparation of MNs from biocompatible polymers approved by the FDA ([@b0185]). The outcomes of human clinical study trial (phase 1) using dissolvable MN arrays to administer a vaccine against influenza, patients had favourable reactions, and the drug delivered initiated favourable therapeutic responses in the human tests ([@b0640]).

Moving forward, the biggest hurdle would be the development of straightforward processes that enable efficient, robust and high throughput production of the polymer microneedles at an industrial scale. Current production methods employ batch production processes, which are limiting ([@b0510]). Polymers used in MN fabrication can be hygroscopic; absorption of water from the production facility compromises the structural integrity and strength of the finished product, affecting the performance of the final MN product ([@b0255]). Huge measures will need to be implemented in production methods and facilities for successful fabrication of MNs. As MN array-based product innovation has been in full force, no pharmacopoeia standards are currently in place.

The successful implementation of MNs may be required to make significant investments in equipment and processing technology. Since no pharmacopoeia standards currently exist for MN array-based products, due mainly to the innovative nature of this technology. As companies propose to introduce MN patches into the pharmaceutical market in the future, the need for standardization and regulation regarding sterility, durability, safety, application and disposal of MNs will arise ([@b0390]). Thus far, the requirements and restrictions related to sterility and safety of the products up to the disposal of MNs after use depended mainly on the application sector ([@b0145]).

Moreover, there is insufficient data on the side effects of polymer MN such as skin irritation, changes in skin barrier function and microbial penetration as well as more investigation are required to select a polymer that minimises the skin irritation ([@b0635]). Polymer deposition from MN has great interest currently as the polymers never used before intradermally in spite of are typically approved pharmaceutical excipients. Regulators may require more information on the amounts of polymer left behind in skin after MN removal and information on clearance rates and routes ([@b0190]). The deposition of polymers inside the human body might be a non-issue in case of single MN administration but could be important if a polymer MN was regularly used, it is theorised that repeated application polymer of MN could lead to distribution and deposition of polymer throughout the body, hepatic accumulation, build-up of polymer in the dermal tissue, and immunological reaction ([@b0390], [@b0635]).

The study conducted by [@b0770] to investigate the effect of repeated application polymeric microneedle arrays on the skin using an animal model. Two types of MN were prepared; hydrogel-forming MN using Gantrez® S-97 BF, and Polyethylene glycol as well as dissolving MN prepared using Gantrez® S-97 BF and, (polyvinyl pyrrolidone). The result shows that all mice displayed mild erythema after MN removal, but no permanent change in skin observed in dissolving MN. In addition, both dissolving and hydrogel-forming MN arrays do not stimulate the humoral immune system or cause infection or trigger an inflammatory response cascade. Nevertheless, the long-term effects of polymer deposition will require further investigation to ensure they do not represent a toxicity issue ([@b0780]).

In general, widespread application of polymer microneedle for transdermal delivery is still pending due to the lack of human clinical trials, and the need for improvements in production scale and cost. The skin and other target tissues are moist and amenable to distortion and contain nerve endings that are painful when stimulated. In administering MNs to these tissues, MN dissolvability, structure, and application method are important factors to consider for MNs. There is also a need for skilled personnel in the administration of the MNs. Although much has been discovered on successful MN application in the skin, much remains to be discovered for its application in other tissues. Future research and developments in MNs will need to consider the structure of the target tissue and the target disease. This will determine the MN design, type of drug that can be used and amounts for effective delivery into the target tissue ([@b0415]).

6. Conclusion {#s0040}
=============

Polymeric microneedles (MNs) are a powerful technology for delivering small chemical molecules to large complex biotherapeutics with established clinical efficacy. MNs based drug delivery through the skin address the shortcoming associated with oral and parental pathways and intended for self-administration at home. The successful development of polymer MNs relies profoundly on the type of polymer used one polymer or mixture of polymers, biocompatibility with drug, design and mechanical strength of the MN. Moreover, animal studies and human studies must be included to evaluate the penetration of MNs through the skin, drug release, pharmacological and toxicity performance. The fundamental studies and commercialization programs must be combined to accelerating the production of polymeric MNs in large-scale, and more effort required to establish guideline regarding the sterilization process, and further awareness of the long-term adverse effects of polymeric MNs in regenerative medicine.
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